Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of AEGR-733 in adults with homozygous familial hypercholesterolemia on background lipid-lowering therapy
2008-007058-36Phase 3Completed
- Sponsor
- Aegerion Pharmaceuticals
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lomitapide in homozygous familial hypercholesterolemia (HoFH), sponsored by Aegerion Pharmaceuticals. Primary endpoint: Percent change in LDL-C at maximum tolerated dose after 26 weeks. Started Jun 2009; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2008-007058-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007058-36.